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 PAbstract
Eradication of virus by sanctuary sites is a main goal in HIV management. The central nervous system (CNS) is a classic model of
sanctuary where viral replication occurs despite a complete viral suppression in peripheral blood. In recent years, nanotechnologies have
provided a great promise in the eradication of HIV from the CNS. We hereby demonstrate for the first time that the structurally complex
antiretroviral drug enfuvirtide (Enf), which normally is unable to penetrate the cerebrospinal fluid, is allowed to cross the blood brain barrier
(BBB) in mice by conjugation with a nanoconstruct. Iron oxide nanoparticles coated with an amphiphilic polymer increase Enf translocation
across the BBB in both in vitro and in vivo models. The mechanism involves the uptake of nanoconjugated-Enf in the endothelial cells, the
nanocomplex dissociation and the release of the peptide, which is eventually excreted by the cells in the brain parenchyma.
© 2015 Published by Elsevier Inc.
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RBackgroundCurrent antiretroviral treatment regimens suppress plasma
HIV-1 RNA and DNA below detectable levels in a consistent
proportion of subjects.1 However, functional cure and eradica-
tion are still beyond our possibilities. One obstacle to such goals
is represented by the difficulty to achieve therapeutic antiretro-
viral concentrations within sanctuary sites where HIV-1 has beenU
N
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the gut-associated lymphoid tissue, the lymph nodes, tissue
macrophages and the central nervous system (CNS).2-4 In
particular, the CNS is considered one of the most important viral
reservoirs. This is mainly due to the presence of macrophages
that promote the inflammatory escalation with subsequent
astrogliosis and neurodegeneration, thus establishing the
so-called NeuroAIDS,5 responsible for neurocognitive disordersntral nervous system; DLS, dynamic light scattering; ECM, endothelial cell
D40, FITC-Dextran 40; FITC, fluoresceinamine; HAART, highly active
spectrometry; MRP, multidrug resistance-associated protein; Papp, apparent
PMA, poly(isobutylene-alt-1-tetradecene-maleic anhydride); RBMVECs, rat
EM, scanning electron microscopy; TEM, transmission electron microscopy;
medica (FRRB), NanoMeDia Project (Regione Lombardia and “L. Sacco”
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with different grades of severity (AIDS dementia complex).
From a clinical point of view, NeuroAIDS is a real challenge
since the blood brain barrier is poorly crossable by most
antiretroviral drugs.2
In the effort toward viral eradication, one of the most
promising strategies is to treat this latent-T cell reservoir, so that
resting cells may be induced to release virions and reactivate,6-9
while preventing HIV-1 entry in uninfected CD4+ T cells. With
this aim it would be important to design new therapeutic
strategies to direct antiretroviral drugs in these HIV sanctuaries,
both to reduce T-cell mediated delivery of the virus into the
sanctuaries and to directly act on HIV-sensitive CD4+ cells
inside these sites (i.e. microglial cells of brain)4.
Nanotechnology is an emerging multidisciplinary field that has
the potential to offer a radical change in the treatment and
monitoring of HIV/AIDS.10-13 The potential advantages in using
nanoparticles for HIV infection treatment include the capacity to
incorporate, encapsulate, or conjugate a variety of drugs in order to
target specific cell populations, grant long-term drug release, and
penetrate into sanctuary sites. With regard to the CNS, the
employment of nanotechnology could allow antiretroviral drugs to
effectively reach this reservoir,14 thus preventing the replication of
the virus and reducing the damages induced by the infection.
In current clinical practice, the first-line antiretroviral therapy is
generally constituted by a combination of two nucleoside reverse
transcriptase inhibitors (NRTI) with a non-nucleoside reverse
transcriptase inhibitor (NNRTI), such as a protease inhibitor or an
integrase inhibitor. Conversely, fusion inhibitors are much less
used because of some well-known limitations such as production
time and costs, difficult administration (subcutaneous injection
twice daily) and adverse effect profile.15 Therefore, fusion
inhibitors are only used in case of resistance or failure of the
HAART.Enfuvirtide (Fuzeon™ fromRocheLaboratories Inc. and
Trimeris Inc.) is a 36-amino acid peptide that targets multiple sites
in gp41, a HIV glycoprotein responsible for the fusion with CD4+
cells.16-18 Enfuvirtide (Enf) inhibits HIV-1-mediated cell-cell
fusion and transmission of cell-free virus while it does not have
substantial activity against HIV-2.19-22 Because of its unfavorable
pharmacological profile, with a half life of approximately 2 h and a
high molecular weight (4.5 kDa), Enf is particularly indicated to
provide a proof of concept of the improved access of antiretroviral
drug to HIV sanctuaries by nanoformulation. Indeed, Enf does not
penetrate the BBB because of its complex structure, and is
therefore not detectable in cerebrospinal fluid (CSF).23
Aim of our study is to demonstrate the ability of iron oxide
nanoparticles coated with PMA amphiphilic polymer (MYTS) to
enhance the permeation of a high-weighted molecule, such as
Enf, across the BBB both in in vitro and in vivo models, and
propose a mechanism for drug delivery across the endothelium.138
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Nanoparticle design
Magnetic nanoparticles (MNP) were synthesized by sol-
vothermal decomposition in organic solvent from organometallic
precursors according to Park et al. protocol.24 MNP were
transferred to water phase using a fluorescent labeled amphi-TE
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philic polymer (PMA).25 Fluorescent-PMA was obtained with
fluoresceinamine 1.0 M (0.5 mL in DMSO) was added to a
0.5 M PMA in CHCl3 (5 mL) and the mixture was left overnight
at RT. Part of this solution (20 μL) was added to MNP (1.5 mg
in CHCl3). The organic solvent was evaporated and sodium
borate buffer (SBB, pH 12, 20 mL) was added obtaining a stable
nanoparticle dispersion which was concentrated in Amicon tubes
(100 kDa filter cutoff) by centrifuging at 3500 rpm for 20 min.
The nanoparticles were washed twice with water resulting in
green labeled PMA-coated nanoparticles highly soluble in
aqueous media (MYTS). MYTS were reacted with an amino-
linker useful for Enf immobilization on the nanoparticles. Enf
was previously labeled with AF660 dye (Invitrogen, Carlsbad,
CA) according to manufacturer’s protocol. The final double
labeled Enf-MYTS are schematically represented in Figure 1, A.
Characterization of the BBB in vitro model
The setting of the BBB in vitro model, based on a co-colture of
RBMVECs and astrocytes, is described in Supplementary
materials. Before each experiment, we checked the trans-BBB
electrical resistance by an EVOM2 Epithelial tissueVolt/Ohmmeter
connected to an Endohm-24SNAP cup (WPI, Germany), obtaining
a suitable value on 90% of the inserts. Moreover, the trans-BBB
apparent permeability coefficient of FITC-Dextran 40 (FD40)
was determined by measuring the flux of the molecule from the
upper to the lower chamber of three BBB systems at 1 h, 2 h and
3 h from the addition of 1 mg mL−1 FD40 in the upper
compartment. The flux through the RBMVECs single layer or
through the empty insert was used as control. The amount of
FD40 recovered in the lower compartment was determined
spectrofluorimetrically and the Papp was calculated from the
mean flux (see Supplementary materials).
In vitro trans-BBB permeation
The permeation of (AF660)Enf, (FITC)MYTS or
(AF660)Enf-MYTS(FITC) across the BBB was assessed on
the in vitro model described above, using four inserts for each
experimental condition. The two formulations were added to the
upper chamber and, after 4 or 7 h of incubation, a defined
volume of ECM was collected by both the upper and the lower
chambers. The fluorescence intensity of the samples was
measured spectrophotometrically. For an exact comparison
between the trans-BBB permeation of free and MYTS-conju-
gated Enf (5 μg mL–1), the FI of the two formulations was used
for normalization, and the final amount of Enf-MYTS in the
upper chamber was 0.1 mg mL–1.
ICP-OES was also used to quantify the amount of MYTS iron
in the collected samples.
Reported results are representative of one of three indepen-
dent experiments.
Plasma concentration measurements in mice
Plasma concentration of free or conjugated Enf was
determined upon intravenous injection AF660-labeled Enf
(0.2 μg g–1 body weight) or Enf-MYTS (12.5 μg g–1 body
weight) in Balb/c mice. We treated four mice per experimental
condition and repeated the experiment twice (for a total of eight
R
E
C
TE
D
 P
R
O
O
F
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
Figure 1. (A) Schematic representation of labeled Enf-MYTS. (B) TEM images of MNP in hexane (left) and MYTS in water (right).
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Ranimals per experimental condition). The amount of injected
Enf-MYTS was calculated normalizing the fluorescence inten-
sity of conjugated Enf to that of the free peptide. After 30 min,
1 h and 6 h postinjection, blood was collected and its
fluorescence intensity was determined spectrofluorimetrically.
After subtraction of background fluorescence, determined in
samples collected from mice before treatment, the amount of Enf
was calculated by using a calibration curve with known amounts
of the compounds dissolved in control plasma samples.U 171
172
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180Ex vivo IVIS imaging
Mice injected with (AF660)Enf or (AF660)Enf-MYTS (three
animals for each experimental group were employed in three
different experiments, for a total of nine mice) were sacrificed
1 h after injection and dissected brains were analyzed in an IVIS
Lumina II imaging system (Calipers Life Sciences, UK), together
with the brains from three non-treated mice. Images were
acquired with a Cy5 emission filter, while excitation wasscanned from 570 to 640 nm and tissue autofluorescence was
removed by spectral unmixing.
Confocal laser scanning microscopy
For the confocal observations of brain cryosections, portions
of the same tissues analyzed by IVIS or of additional tissues
isolated from mice injected with 0.2 μg g–1 body weight
(AF660)Enf, or 12.5 μg g–1 body weight (FITC)MYTS,
(AF660)Enf-MYTS or (AF660)Enf-MYTS(FITC) (three ani-
mals for each experimental group), were fixed, freezed in liquid
nitrogen and cryosectioned. Cryosections were counterstained
with DAPI and NeuroTrace 530/615 fluorescent Nissl stain or
immunodecorated with anti-CD31.
For the confocal microscopy of RBMVECs (three inserts for
each experimental condition), cells on insert were fixed and
immunodecorated with anti-CD31 and DAPI.
Images were acquired by a Leica TCS SPE confocal
microscope and the intracellular distribution of AF660 and
FITC signals was analyzed by ImageJ software.
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three inserts or mice brain sections for each experimental condition.
Scanning and transmission electron microscopy
For TEM analysis, MYTS were dispersed under sonication in
water (50 μg mL–1) and a drop of the resulting solution was
placed on a formvar/carbon-coated copper grid and air-dried.
RBMVECs layered on inserts and exposed or not to 0.1 mg
Enf-MYTS or MYTS, and sections of mice brains, exposed
in vivo to the same nanoformulates (12.5 μg g–1 body weight),
were analyzed by TEM, by fixing small portions of cells-bearing
inserts (n = 3) or tissues (pieces obtained from the same brains
employed for confocal microscopy analyses) in 2.5% glutaral-
dehyde. For scansion electron microscopy analyses, other small
portions of the RBMVECs-bearing inserts were fixed and
processed as described in Supplementary materials.
Histopathology
Brain, liver, kidneys, spleen and lung samples obtained from
three Balb/c mice, whose brains were analyzed by confocal
microscopy, were fixed in 10% buffered formalin for at least
48 h and embedded in paraffin. Three μm sections were cut,
stained with hematoxylin and eosin and examined blindly.
Statistical analysis
All mean values ± SE reported in Results section and in
Supplementary materials were compared by Student’s t test.259
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Results
Nanoparticle characterization
MNP and the final Enf-MYTS, synthesized as described in
Methods and Supplementary materials, were characterized in
size and shape by DLS and TEM (Figure 1, B). MNP had a
hydrodynamic diameter of 18.8 nm ± 2.1 in hexane. After the
phase transfer, MNP maintained the original average crystal size
(8 nm by TEM), and the final nanoparticle shape was uniformly
spherical, with a hydrodynamic diameter of 23.9 ± 2.0 nm
(MYTS in water) as determined by DLS. After drug conjugation,
the nanoparticle size increased up to 35.2 ± 2.2 nm. The pH
value of the suspension was around 5.5 and the zeta potential
obtained at this pH value was −29.58 ± 1.90 mV, likely
suggesting a high stability of Enf-MYTS with minimal
aggregation in water medium at this pH. Indeed a zeta potential
value higher than ±30 mV is generally required for a colloidally
stable nanoparticle dispersion.26,27
Nanoconjugated enfuvirtide crosses the in vitro BBB model
The efficiency of MYTS in increasing the trans-BBB
permeation of Enf was first evaluated on an in vitro BBB
model consisting of a double layer of astrocytes and RBMVECs.
Before treatment, the integrity of our experimental model was
validated by measuring TEER and by determining the trans-BBB
apparent permeability of the Dextran 40. In all BBB models
devoted to the subsequent experimental phase, we recorded a
mean TEER value higher than 400Ω cm2. BBB selectivity to theTE
D
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Dextran 40 labeled with FITC (FD40) was assessed in some
additional inserts by measuring the trans-BBB flux over 3 h
(Figure S1). The resulting Papp (0.10 ± 0.03 × 10
–7 cm s–1,
mean ± SE, n = 6) confirmed the production of a very tight
barrier. SEM observations showed the presence of a uniform
layer of endothelial cells (Figure S2A), and TEM images clearly
demonstrated that cells were connected by well-structured tight
junctions (Figure S2B).
The permeability of Enf, MYTS and Enf-MYTS across the
BBB model was determined by labeling the peptide and the
nanoparticle with AF660 and FITC, respectively (Figure 1, A).
The nanoparticle suspensions were added in the upper chamber
of the experimental apparatus and their passage through the BBB
model was assessed after 4 and 7 h of incubation by measuring
their fluorescence intensity (FI) into the lower chamber. We
found that only a small fraction of free Enf was able to cross the
BBB in vitro: after 4 h, Enf FI in the lower chamber was about
0,15 % of Enf FI added in the upper chamber, and the percentage
increase of FI in the lower chamber over the subsequent 3 h of
incubation was 30% (Figure 2, A). Conjugation of Enf to the
nanoparticle did not significantly affect its FI in the lower
chamber within the first four hours, but it was able to greatly
increase its permeation across the BBB (by over 170%) between
4 and 7 h of incubation (Figure 2, A). Surprisingly, the
percentage increase of the FITC FI in the lower chamber
calculated between 4 and 7 h, which is associated to MYTS
permeation across the BBB, was only 10%, and therefore much
lower than that of the conjugated peptide in the same time span
(Figure 2, B). The great difference between the % increase in
lower chamber of AF660 (conjugated to Enf) and FITC
(conjugated to MYTS) after incubation with the Enf-MYTS
nanocomplex strongly suggested that the two components did
not have the same fate when crossing the BBB, and that they
likely dissociated into the barrier to be processed separately. The
permeation of MYTS through the BBB was also assessed by
measuring the iron content in the solution collected by the lower
chamber by ICP-OES: we found that the percentage increase of
iron recorded between 4 and 7 h was only 1.84 ± 0.04 (mean ±
SE, n = 8) for both MYTS and Enf-MYTS.
Then, we measured the FI of the three formulations in the
lower chamber of the BBB apparatus after 24 h of incubation.
We observed that the Enf trans-BBB permeation was enhanced
between 7 and 24 h of incubation by 175% (Figure 2, A), likely
because of increased leakage of the RBMVEC barrier over the
time. However, the effect of the nanocomplexation on the
permeation of Enf across the BBB was still remarkable: the
percentage increase of AF660 FI in the lower chamber between 7
and 24 h of exposure to Enf-MYTS reached 745% (Figure 2, A).
By contrast, the percentage increase of FITC FI in the lower
chamber was about 20% for both MYTS and Enf-MYTS
(Figure 2, B), thus underlining a discrepancy between the FI
recorded for Enf and MYTS after incubation of the BBB with
Enf-MYTS. The percentage increase of iron content in the lower
chamber between 7 and 24 h was still negligible and comparable
for both conjugated and unconjugated nanoparticles (1.89% ±
0.03, mean ± SE, n = 8).
In parallel, we performed a confocal microscopy analysis of
the upper side of the insert after 7 h of incubation with Enf or
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Figure 2. Percentage (%) increase of FI of free or conjugated (AF660)Enf (A) or (FITC)MYTS (B) in the lower chamber of the BBB in vitro system calculated
between 4 and 7 h, and 7 and 24 h, from the addition of labeled Enf, MYTS and Enf-MYTS into the upper chamber. Mean ± SE of 4 replicates; **P b 0,001
and *P b 0,05, Enf-MYTS vs Enf (Student’s t test) (C) Confocal laser-scanning micrographs (single optical sections) of RBMVECs after 7 h of incubation with
free Enf or Enf-MYTS. Enf andMYTS are labeled with AF660 (red) and FITC (green) respectively; nuclei are stained with DAPI (cyan) and endothelial cells are
immunodecorated with anti-CD31 antibody (blue); scale bar: 10 μm. (D) Overlay of the signal intensity plots of Enf andMYTS along a one-pixel line covering a
cytoplasmic portion of the cells.
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Figure 3. Analysis of brains isolated from non-treated mice (NT) or mice exposed for 1 h to free or conjugated AF660-labeled enfuvirtide. (A) Epf images of
isolated brains, where Epf intensity is expressed as radiant efficiency. (B) Averaged Epf intensity of isolated brains where Epf values have been normalized on
fluorescence intensity of injected solution in order to keep into account the differences in intrinsic fluorescence emission for each preparation; mean ± SE of 9
different brains for each experimental condition; *P b 0,01 (Student’s t test). (C) Confocal laser-scanning micrographs (single optical sections) of brain
cryosections; images from control animals (NT) or from animals treated with free or nanocomplexed enfuvirtide (red) have been overlaid on the corresponding
images reporting nuclei (blue) and neuronal cytoplasm (yellow), counterstained with DAPI and NeuroTrace 530/615, respectively (right column); brightfield
(BF) images are reported on the left; dashed lines highlight the vessel boundaries; bar: 10 μm.
6 L. Fiandra et al / Nanomedicine: Nanotechnology, Biology, and Medicine xx (2015) xxx–xxxEnf-MYTS. Figure 2, C shows that while free Enf was not
internalized by the RBMVECs, the conjugation of the peptide
to the nanoparticles allowed it to deeply enter into the cells,
confirming the enhanced permeability of Enf when nanocon-
jugated. The merge image of the cells incubated with
Enf-MYTS revealed that the AF660 and the FITC fluorescencewere mostly non-overlapping (Figure 2, C and D). These
image data, combined with the great difference in the
trans-BBB permeation rate observed between the two
components, strongly suggested that a dissociation of the
peptide from the nanoparticle might have occurred in the
endothelial layer.
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Figure 4. Confocal laser-scanning micrographs (single optical sections) of brain cryosections from non-treated mice (NT) or mice exposed for 1 h to
(AF660)Enf, (FITC)MYTS or (AF660)Enf-MYTS(FITC); conjugated or free AF660-Enf (green) and FITC-MYTS (red) have been overlaid each other and with
CD-31 stained endothelial cells (blue); brightfield (BF) images are reported on the left; bar: 10 μm.
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gated enfuvirtide
Trans-BBB permeation of MYTS-conjugated Enf was then
assessed in vivo in Balb/cmice intravenously injectedwith free Enf
or with the same peptide conjugated to nanoparticles. We decided
to follow the bioavailability and biodistribution of Enf, by labeling
the peptide with AF660whose efficiency as in vivo probe had been
previously reported in mice.28,29 Firstly, plasma concentration of
free or conjugated Enf was monitored at 30 min, 1 h and 6 h after
injection in eight different animals for each experimental
condition, to verify the effect of nanoconstruct on peptide
bioavailability. We observed a maximal concentration of both
free or conjugated drug in the blood streamwithin 1 h postinjection
and a strong decrease over the following hours, up to negligible
levels at 6 h postinjection. Moreover, Enf concentration in plasma
appeared reduced by conjugation to MYTS and therefore lessavailable for the potentially infected organs, including brains
(Figure S3). Othermicewere injectedwith Enf or Enf-MYTS (nine
for each experimental condition) to be sacrificed at 1 h
postinjection, together with three untreated animals (controls).
Fluorescence imaging of dissected brains revealed a significant
accumulation of both free and nanoformulated Enf in this organ at
1 h postinjection, as pointed out by the strong Epf signal not
observed in the brain of non-treated mice (Figure 3, A), feasibly
due to the peptide content in the blood circulation of brain.
Neverthless, Epf intensity associatedwith nanoformulated Enf was
stronger than that of free Enf (Figure 3, A, B), thus suggesting a
higher accumulation of the nanoformulated peptide in this organ
despite its lower bioavailability. To determine if the observed
increased concentration of Enf in the brain was really associated to
an increased permeation of the drug across BBB by effect of the
nanocomplexation, we analyzed the interaction of Enf and
Enf-MYTS with BBB cells and of their localization in the
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Figure 5. Histopathological analysis of brain, spleen, lung, liver and kidney dissected from non-treated (NT) mice, or from mice injected with MYTS, Enf and
Enf-MYTS. Hematoxylin-eosin, OM ×40.
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perivascular space. Cryosections of mice brains excised 1 h
postinjection of Enf or Enf-MYTS were analyzed by confocal
microscopy. Figure 3, C shows enhanced fluorescence intensity in
brain capillaries in samples treated with the nanoconjugated Enf
when compared to the free peptide, where instead fluorescencewas
only slightly higher than control autofluorescence. In addition,
nanocomplexation of Enf induced a spreading of fluorescence
outside the boundaries of the vessel.
To confirm the efficacy of MYTS in driving Enf into the
endothelial cells of brain capillaries and finally exerting an
efficient trans-BBB permeation of the drug, we injected mice
with MYTS, Enf or Enf-MYTS (three mice for each experimen-
tal condition) and analyzed the localization of the different
compounds in brain sections after 1 h from injection, by means
of the differential labeling of Enf and MYTS with AF660 and
FITC, respectively (Figure 4). Immunodecoration of the
endothelial cells with anti-CD31 antibody revealed a huge
intracellular accumulation for MYTS. As expected, the ability of
free Enf to enter BBB endothelial cells and reach brain
parenchyma was negligible, while conjugation of the peptide
to the nanoparticles allowed it to cross the barrier. Merge
between Enf and MYTS signals in samples treated with
Enf-MYTS clearly showed that only the peptide was able to
diffuse outside the BBB, while nanoparticles were restricted to
the vessel endothelium. This result, in agreement with in vitro
observations, further suggested the dissociation of the nanocom-
plex within endothelial cells, with subsequent excretion of Enf.
The systemic toxicity of administered formulations was then
assessed by histopathological examination of brain, liver,
kidneys, spleen, and lungs isolated 1 h after Enf, MYTS orTEEnf-MYTS injection. Analysis was performed on organsspecimens from three different animals for each experimental
condition. No histological lesions were observed in the analyzed
organs (Figure 5).
Fate of MYTS in RBMVECs
The mechanism of MYTS entry and trafficking into the
RBMVECs was investigated by TEM analysis on BBB-bearing
inserts after 4, 7 or 24 h from the addition of Enf-MYTS in the
upper chamber. Figure 6, A shows that, at 4 h of incubation,
nanoparticles were either attached to the plasma membrane of the
endothelial cells or internalized in the cytosol. The lack of
membrane invaginations and the presence of free nanoparticles in
the cytoplasm suggest that a non-endocytotic mechanism is
involved in the internalization of MYTS by RBMVECs, as
confirmed also byTEM images of brain samples exposed in vivo to
the nanocomplex (Figure S4). Macropinocytosis rafts were also
visible where a large number of nanoparticles came in contact with
the cellular membrane. Once internalized, MYTS accumulated
into large cellular compartments (Figure 6, A and B), and after
24 h of incubation, they were also detected into lysosomes
(Figure 6,C). The same result was obtained by incubating the cells
with the unconjugated MYTS.Discussion
The BBB is the boundary that isolates brain tissues from the
substances circulating in the blood and at the same time allows
water and small lipophilic molecules to freely access the brain in
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Raccordance with their concentration gradients. Within thisbarrier, the brain microvascular endothelial cells, phenotypically
different from the endothelial cells of the peripheral circulation,
hamper the filtration of therapeutic drugs, preventing them to
reach the pathological tissues behind them. To permeate through
the BBB, molecules need to be lipid soluble with a molecular
weight b400 Da. Heavier and larger molecules, which are
unable to diffuse through the BBB because of their size, weight
and/or polarity, could cross the BBB only if transported by
receptor-mediated transcytosis using ligands that bind specific
BBB receptors. Therefore, drugs permeability across the BBB
represents a clinical and biological challenge.
It is well established that a double correlation between HIV
infection and the brain exists: HIV replication plays a major role
in neurological diseases, and CNS is one of the main viral
reservoir. During the acute phase of infection HIV-1 rapidly
infiltrates the CNS; there the viral replication can occur despite a
complete drug-induced suppression of the virus in the peripheral
blood. Noteworthy, while about 50% of HIV-infected patients
are affected by neurological disease, evident morphologicalalterations in CNS are observed in at least 80% of AIDS patients
autopsies.30 The acclaimed model for HIV-related injury of CNS
involves the release from infected or activated glial cells
(microglia and astrocytes) of numerous neurotoxic viral or
cellular factors, which lead to neuronal damage and death, and of
chemoattractants able to promote infiltration of infected and/or
activated monocytes.4
In NeuroAIDS prevention, nanotechnology has been intense-
ly explored with the aim to develop novel and promising drug
delivery systems, and several experimental attempts have been
carried out in last years in order to enhance the BBB permeability
toward antiretroviral drugs. Indeed, BBB has been demonstrated
to be impermeable to 98% of antiretroviral drugs.31 In 2006, Kuo
and colleagues have incorporated two antiretroviral drugs,
zidovudine and lamivudine, into polymeric polybutylcyanoa-
crylate (PBCA) nanoparticles, showing a 8-20 and 10-18 fold
increase in BBB permeation, respectively.32 However, polymer-
ic nanoparticles are not suitable as carriers for polar or ionic
drugs, and degradation of PBCA can produce toxic formalde-
hyde by-products.31 Other biocompatible polymers, such as
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polylactide, have been studied as novel nanocarriers for CNS
drug delivery, but a transient inflammatory response has been
reported.31 Conjugation of the protease inhibitor saquinavir with
transferrin-conjugated quantum dots has shown improved BBB
penetration in vitro, by exploiting an active transport mechanism
mediated by transferrin receptors; nevertheless, in vivo results
are still missing.14 Other nanocarriers such as liposomes are
inefficient for loading with water-soluble drugs.31
In our study we have designed and developed a novel
nanodrug consisting of an iron oxide nanoparticle coated with a
suitable amphiphilic polymer and functionalized with the
antiretroviral peptide enfuvirtide. Although rarely used in
clinical practice, we selected Enf for two main reasons. First, it
has proven effective as a non-selective inhibitor of HIV-1 fusion
with cells, able to preclude virus entry regardless its co-receptor
tropism. The blockade of virus entry into cells is relevant in view
of the use of drugs that purge the latent reservoir, damming the
circulating HIV-1 pool of virus that should not re-infect new
cells. Secondly, Enf is one of the most structurally complex
antiretroviral molecules, therefore ideal for testing the efficacy of
our nanoconstruct as a drug delivery system to the brain.
So far, the use of iron oxide nanoparticles as antiretroviral
carriers has been poorly investigated in vivo.31 In the present work,
our polymer-coated iron oxide nanoparticles (namelyMYTS) have
proven to be promising as CNS drug delivery system for
antiretroviral drugs, by taking advantage of their intrinsic
propensity to cross the BBB. We observed in vitro an increased
permeation of nanoformulated Enf across BBB up to 170% upon
3 h of incubation. Moreover, conjugated Enf showed increased
epifluorescence intensity in mice brain, as a result of its huge CNS
accumulation. Electron microscopy images suggested that endo-
cytosis is not likely responsible for the internalization of MYTS in
the endothelial cells, even though the presence of a large number of
nanoparticles on the cell surface activated the production of
macropinocytosis membrane ruffles. Rather, the presence of free
nanoparticles in the cell cytoplasm strongly suggests that their
internalization mainly occurred by a passive diffusion, probably
mediated by the absorption of the amphiphilic coating on the cell
membrane. In previous studies, it has been assumed that polymer
aggregates carrying hydrophobic groups should have the same
affinity for brain endothelial cell membranes of pluronic block
copolymers33, whose absorption on cell membrane induces a
structural alteration of the lipid bilayer.34 Membrane fluidization
allows the pluronics micelles to enter the microvessel endothelial
cells and deliver their cargo into the intracellular environment.34
Once into the cell, nanoparticles were sequestered by huge
endosome-like compartments and then directed to lysosomes. Our
data indicated that Enf dissociated from MYTS in the endothelial
cells to be efficiently excreted into the outside environment. The
dissociation mechanism requires further studies to be elucidated,
but it could involve the degradation of the PMA shells bearing the
peptide. PMA degradation feasibly started into the more mature
endosomal compartments, as an effect of the increased acidity and
enzymatic activity of their inner environment, to be then completed
within lysosomes. Concerning Enf efflux, it is known that foreign
substances are usually rejected by the BBB through an efflux
mechanism based on transporters such as P-glycoprotein and
multidrug resistance-associated protein (MRP).35 The brain-dir-P
R
O
O
F
ected efflux of Enf could occur via MRP4, a protein expressed on
the abluminal membrane of the brain capillary endothelial cells,
which were proven to mediate the excretion of different drugs,
including some antiretrovirals.36 Histopathological analysis of
brain, spleen, lung, liver and kidneys dissected frommice uponEnf
treatment, confirmed that this antiretroviral drug does not exert
toxic effects.Moreover, the lack of any organ lesion in the presence
of circulating MYTS is a clear evidence of the systemic safety of
these nanoparticles at the experimental dosage, further supporting
their great potential as drug delivery system across the BBB.
In conclusion, this is the first documented experience of a
nanotechnological engineering of the complex antiretroviral
drug enfuvirtide, which conferred to this large peptide the
capability to cross the BBB. Whether and how the propensity of
Enf nanoconjugate to cross the BBB could affect the viral
replication in the CNS sanctuary remain to be established, and
further studies will be performed to assess the antiviral efficacy
of Enf after trans-BBB permeation. However, at present, our
results represent an important step forward toward HAART-me-
diated HIV eradication from the CNS reservoir. Since MYTS
nanoparticles can be loaded with multiple drugs of different
classes, the present study suggests a straightforward approach for
targeting various phases of viral replication in the CNS.E
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